Navigation Links
YM BioSciences provides update on AeroLEF(TM) clinical development program
Date:1/17/2008

recently reported that its lead drug, nimotuzumab, is in numerous trials internationally including a Phase III randomized trial in adult glioma and a Phase II/III randomized trial in patients with advanced pancreatic cancer. Data from the fully recruited Phase III trial in Europe in children with inoperable brain cancer, if positive, are expected to be submitted to the EMEA for marketing approval.

About AeroLEF(TM)

AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. In contrast to fixed-dose approaches to opioid delivery, where a significant titration period is often required to determine the suitable dose for the patient, AeroLEF(TM) is being developed as a non-invasive delivery system designed to enable patients to self-titrate. Using AeroLEF(TM), patients can identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such f
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... Asia-Pacific Speech Analytics market report defines and segments the ... of revenue. This market is estimated to grow from ... at a Compound Annual Growth Rate (CAGR) of 23.9% ... of the Asia-Pacific Speech Analytics market report to get ... provides a glimpse of the segmentation in the market, ...
(Date:10/19/2014)... According to market research report “Outdoor Wi-Fi Market ... Global Advancements, Forecasts and Analysis (2013 - 2018)", ... with analysis and forecasting of the global revenues. ... and the restrains for this market with the ... Browse 65 market data tables and 69 figures ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 4
... 26 Amedica Corporation, an,orthopedic implants company focused ... U.S. Food and Drug Administration,has granted 510(k) marketing ... Valeo Pedicle Screw system is a low profile ... aimed at allowing surgeons,greater flexibility in the positioning ...
... WALTHAM, Mass., Nov. 26 Millennium Research ... data from both orthopedic surgeons and rheumatologists, shows ... Q3 2007 compared to Q3,2006. While treatments are ... the products they use in these procedures., ...
... Opportunity Presented, CHARLES TOWN, W.Va., Nov. ... RBRM), a provider of treatment for,diabetic peripheral ... successfully concluded analysis of the recent volatility ... the Board of Directors., (Logo: ...
Cached Biology Technology:Amedica Receives FDA 510(k) Clearance for Valeo(TM) Pedicle Screw System 2Hyaluronic Acid Knee Procedures Grow 38% from Q3 2006 to Q3 2007 2ReBuilder Medical Technologies, Inc.'s Recent Stock Price Volatility Explained 2
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... rapidly and to an unexpected extent. The outbreak does ... the virus shows a new disease dynamic in regions, ... reason, the German National Academy of Sciences Leopoldina, acatech ... the Union of the German Academies of Sciences and ... today. , In the statement the academies call for ...
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... winds caused by global warming, seeds and pollen are being ... a couple of degrees may increase the dispersal of plants ... forest clearings after felling or forest fires. University ... the impact of global warming on seed and pollen dispersal. ...
... dog owner has not come home to a broken vase ... the house? By ingeniously setting up conditions where the owner ... an offense, Alexandra Horowitz, Assistant Professor from Barnard College in ... dogs in the recently published "Canine Behaviour and Cognition" Special ...
... discovered a potential new way to treat childhood epilepsy ... Gabriella D,Arcangelo and her colleagues have published their research ... (in press) and the paper has just appeared ... the researchers are investigating the molecular basis of the ...
Cached Biology News:Global warming increasing the dispersal of flora in Northern forests 2What really prompts the dog's 'guilty look' 2Rutgers research tackles childhood epilepsy 2
... controls for monitoring Aldolase tests. 2 ... with targeted manufacturing values at 4 ... 3 IU/L. 30-day shelf life ... C. Level 1: 3 x 3 ...
Request Info...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Recombinant Mouse Noggin...
Biology Products: